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Abstract
Introduction: We have examined expression of microRNAs (miRNAs) in ependymomas to identify molecular markers of
value for clinical management. miRNAs are non-coding RNAs that can block mRNA translation and affect mRNA stability.
Changes in the expression of miRNAs have been correlated with many human cancers.
Materials and Methods: We have utilized TaqMan Low Density Arrays to evaluate the expression of 365 miRNAs in
ependymomas and normal brain tissue. We first demonstrated the similarity of expression profiles of paired frozen tissue
(FT) and paraffin-embedded specimens (FFPE). We compared the miRNA expression profiles of 34 FFPE ependymoma
samples with 8 microdissected normal brain tissue specimens enriched for ependymal cells. miRNA expression profiles were
then correlated with tumor location, histology and other clinicopathological features.
Results: We have identified miRNAs that are over-expressed in ependymomas, such as miR-135a and miR-17-5p, and down-
regulated, such as miR-383 and miR-485-5p. We have also uncovered associations between expression of specific miRNAs
which portend a worse prognosis. For example, we have identified a cluster of miRNAs on human chromosome 14q32 that
is associated with time to relapse. We also found that miR-203 is an independent marker for relapse compared to the
parameters that are currently used. Additionally, we have identified three miRNAs (let-7d, miR-596 and miR-367) that
strongly correlate to overall survival.
Conclusion: We have identified miRNAs that are differentially expressed in ependymomas compared with normal
ependymal tissue. We have also uncovered significant associations of miRNAs with clinical behavior. This is the first report of
clinically relevant miRNAs in ependymomas.
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Introduction
Ependymoma is a common pediatric central nervous system
(CNS) tumor that is believed to originate from ependymal cells
located in the lining of ventricular surfaces in the brain [1].
Outcomes for children with ependymoma have not significantly
changed over the past several decades despite advances in
neurosurgical techniques and adjuvant therapy. Attempts to
predict patient outcome have been limited by the heterogeneous
clinical behavior of patients with ependymoma and many
contradicting studies of existing clinical, pathologic and biologic
prognostic markers. Gross total resection remains the single most
important predictor of overall and relapse-free survivals in
pediatric ependymoma [2]. Treatments currently used in the
clinics, such as radiotherapy and standard-dose chemotherapy,
have resulted in improved outcome, but we are in need of
biomarkers for better diagnosis, prognosis and for management of
disease progression. Histopathologic analysis is not predictive of
clinical behavior, such as the likelihood of recurrence [1,2].
Hence, there is a need for studies aimed at the identification of
molecular markers of clinical value.
MicroRNAs (miRNAs) are short non-coding RNAs (approx-
imatelly 20 nucleotides) that act by blocking messenger RNA
translation, having a major impact in the regulation of protein-
coding gene networks and pathways [3]. They also work as master
regulators of gene expression, and they have been associated with
a wide range of biological processes, including differentiation,
proliferation and apoptosis [4]. miRNAs have also been implicated
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general, miRNAs that are over-expressed in tumors contribute to
oncogenesis by down-regulating tumor supressor genes (e.g. miR-
21 regulating PTEN) [5], whereas those with reduced expression
in tumors may cause derepression or increased expression of an
oncogene (e.g. let-7 regulating RAS, MYC and HMGA2) [6,7].
Cancer-associated miRNAs have also been identified as regulators
of the p53 gene network [8], and have been used as classifiers to
subgroup different tumor types that are not easily categorized by
traditional pathology and histology [9]. Expression profile analyses
have revealed miRNAs that can either promote [10] or strongly
suppress tumor metastasis [11]. Therefore, there is strong evidence
that miRNAs are implicated in different steps of tumorigenesis,
from tumor initiation, tumor maintenance, and progression to
metastasis. However, limited data on miRNA expression in
ependymoma has been previously published.
In this study, we have compared the miRNA expression profile
of thirty-four ependymoma samples to normal brain controls by
TaqMan Low Density arrays (TLDAs). Normal brain tissue
further enriched with ependymal cells were used as normal
controls. First, we analyzed and compared the correlation of
miRNA expression profiles using paired frozen (FT) and paraffin
(FFPE) tissue from the same patients, which was done as a ‘‘proof
of principle’’ to demonstrate that paraffin-embedded specimens
could be used reliably for this type of analysis. Once verified, we
proceeded to analyze the miRNA expression profiles of multiple
ependymomas using FFPE blocks. We correlated miRNA
expression profiles with clinicopathologic parameters, morpho-
logical features and location of the tumor in the brain. Using this
strategy, we have been able to generate a miRNA signature that
can distinguish normal ependymal cells from ependymomas.
Interestingly, we have identified a miRNA, miR-485-5p, that is
down-regulated in ependymomas and putatively targets members
of the TGFbeta family of genes. Using both univariate and
multivariate Cox regression analysis, we were able to identify
miRNAs whose differential expression in ependymoma was
associated both with time to relapse and overall survival. More
specifically, we have identified a cluster of miRs on human
chromosome 14q32 that correlates to Time to Relapse by both
Cox regression analysis and Kaplan-Meier curves. One such
miR, miR-203, was identified as an independent marker for
tumor relapse even when factoring in the clinicopathologic
variables that are currently utilized in the clinics for prediction of
clinical behavior. In addition, three miRNAs (let7d, miR-596 and
miR-367) were identified as better predictors for Overall
Survival.
Materials and Methods
Patients and samples
Tumor samples and normal brain specimens were collected
retrospectively from the Falk Brain Tumor Tissue bank at
Children’s Memorial Hospital (Chicago, IL) under an IRB-
approved protocol. Both FFPE and frozen specimens of
ependymoma were obtained from pediatric patients treated
between 1997 and 2010. Initially, we collected 45 tumor FFPE
blocks and profiled microRNAs for all of them. From these, just 34
samples passed our pipeline for analysis based on RNA quality,
quantity and also after a stringent analysis using the internal
controls from the TLDA microRNA arrays. Normal specimens in
our study represent core biopsies of the lateral ventricular lining of
the basal ganglia and thalamus of patients who died from non
brain-related illnesses, which were microdissected and enriched for
ependymal cells. Clinicopathologic information such as age, tumor
location, time to relapse and overall survival for each ependymo-
ma specimen were also collected by retrospective medical record
review (Table 1).
RNA extraction
For frozen tissue, a sample of approximately 0.5 cm
3 in
dimension was used for RNA extraction. Total RNA was
extracted using a Trizol standard protocol (Invitrogen, Carlsbad,
CA). For FFPE samples, total RNA was isolated from five to
twenty 10 mm-thick tissue sections using the Ambion RecoverAll
kit (Ambion/Applied Biosystems, Foster City, CA) according to
the manufacturer’s instructions. Total RNA quantity and quality
were evaluated using a spectrophotometer (Nanodrop ND-1000,
Thermo Scientific, Wilmington, USA) and agarose gel electro-
phoresis.
Quantification and confirmation of microRNA expression
TaqManH Low Density Arrays (TLDAs) v1.0 (Applied
Biosystems, Foster City, CA) were used to quantify the expression
levels of 365 mature miRNAs and controls. These microRNAs
were selected based on the customized array manufactured by
Applied Biosystems (version 1.0). It is important to note that this
TLDA array contained some microRNAs already associated to
human cancers. A complete list of the microRNAs that are present
in the array is shown on Table S1. Reverse Transcriptase (RT)
reactions were done according to the manufacturer’s instructions
in a 7900HT Fast Real-Time PCR system as described by
Raymond et al., 2005 and Chen et al., 2005 [12,13]. RNA was
purified as described above and each RT reaction contained
purified total RNA and reagents from the TaqManH microRNA
Reverse Transcription Kit. Reactions were run in a 384-well
TLDA block at 94.5uC for 10 min, followed by 40 cycles at 97uC
for 30 s and 60uC for 1 min. Individual miRNA expression
analysis for miR-135a, miR-17-5p, miR-485-5p, miR-383 and
miR-34a were performed in triplicate in 96 well plates using the
TaqManH Individual miRNA assays (Applied Biosystems) accord-
ing to the manufacture’s instructions.
Bioinformatic analysis and microRNA target identification
Putative targets for all differentially expressed miRNAs listed on
Table S2 were predicted using combined bioinformatics methods
and literature search. Both the GOmir software (http://bioacad-
emy.gr/bioinformatics/projects/GOmir), and the GeneGo suite
(http://www.genego.com/) were utilized. The candidates that
were selected by these analyses were then ascertained using
microarray data from gene expression (Illumina, CA, USA). The
values of expression were normalized and ependymoma samples
were averaged against all normal samples.
Statistical analysis
For all miRNA quantification experiments, cycle threshold (Ct)
values greater than 35 were excluded. Values were then
normalized against the expression levels of RNU48 and Delta
Ct values were calculated using Real-Time StatMiner software
(Integromics TM, Philadelphia, PA). Multi-Experiment Viewer
v4.1 (http://www.tm4.org/mev.html) was used to generate
unsupervised and supervised hierarchical clusterings based on
support tree average linkage with Pearson and Eucledian
correlations. The Empirical Bayes Moderated t-test was used by
the StatMiner software (Integromics, TM) to generate Delta-Delta
Ct values for each comparison. P-values were adjusted using the
FDR Benjamini-Hochberg method, and significance was attributed if
FDR,0.05 for all analyses. Fold changes were calculated by
miRNAs as Biomarkers in Ependymoma
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2D(DCT)
(Log10RQ=0 corresponds to no expression change; Log10RQ=1
means that the test sample is expressed at a level 10 times greater
than that of the calibrator sample; Log10RQ=21 means that the
test sample is expressed at a level 10 times lower than that of the
calibrator sample). MiRNA expression levels of normal controls
and tumor tissues were also evaluated using the analysis of
variance (ANOVA).
miRNA expression analyses of association with clinical variables
were conducted using Wilcoxon Rank Sum test. Time to relapse
or recurrence-free survival, and overall survival (OS) were
analyzed for different groups of clinical variables with the log-
rank test and Kaplan-Meier curves were thus generated. A
multivariate Cox regression model was used to select significant
clinical variables and miRNAs to predict time to relapse and
overall survival time in the patient cohort herein investigated. A
survival tree analysis method was used to determine thresholds of
cut-off points for selected miRNA expression in order to generate
Kaplan-Meier curves for time to relapse. All analyses were
conducted using the SAS 9.2 software (SAS Institute Inc., Cary,
NC, USA), and the R package (R Development Core Team,
Vienna, Austria, http://www.R-project.org).
Table 1. Clinicopathologic characteristics of the ependymoma samples used in this study.
Sample Sex
Age at
Diagnosis
(years)
Tumor
Location Specimen
Treatment
Prior to
Surgery
Age at
Surgery
(years)
WHO
Grade*
Specimen
Time to
Relapse
(years)
Patient
Status
Follow-up
(years)*
1A F 8.2 ST Recurrent RT 17.2 II 0.9 DOD 10.6
1B F 8.2 ST Recurrent C/RT 18.1 II 0.2 DOD 10.6
2 M 7.0 IT Recurrent RT 16.2 II 0.6 DOD 10.0
3A F 16.4 ST Primary None 16.4 III 0.4 NED 8.8+
3B F 16.4 ST Recurrent None 16.8 III 1.5 NED 8.8+
3C F 16.4 ST Recurrent RT 18.3 II NR NED 8.8+
4A M 1.2 IT Recurrent C 6.2 III 1.2 DOD 11.2
4B M 1.2 IT Recurrent C 7.5 II 1.7 DOD 11.2
5 M 2.2 ST Recurrent None 3.9 II NR NED 13.4+
6A F 9.2 IT Recurrent C/RT 13.2 II 0.5 DOD 6.8
6B F 9.2 IT Recurrent C/RT 13.8 II 1.1 DOD 6.8
6C F 9.2 IT Recurrent C/RT 14.9 II 0.8 DOD 6.8
7 F 7.6 IT Primary None 7.6 II 1.2 DOD 2.4
8 F 9.7 IT Recurrent C/RT 14.6 II NR NED 13.1+
9 M 5.2 IT Recurrent C/RT 6.6 II 2.2 NED 7.1+
10 F 0.2 IT Primary None 0.2 III 0.6 DOD 0.6
11 M 0.9 IT Primary None 0.9 II 1.0 DOD 7.1
12A F 1.1 IT Primary None 1.1 III 1.8 DOD 4.0
12B F 1.1 IT Recurrent C/RT 3.0 III 0.2 DOD 4.0
12C F 1.1 IT Recurrent C/RT 4.5 III 0.3 DOD 4.0
13 F 6.3 ST Recurrent None 8.1 III 1.2 NED 10.7+
14 F 15.4 IT Primary None 15.4 II 0.3 DOD 2.5
15 F 1.9 IT Primary None 1.9 III 0.4 DOD 0.5
16 M 4.1 IT Recurrent C/RT 11.0 III 0.2 AWD 10.3+
17 M 1.3 IT Primary None 1.3 II 1.2 DOD 1.4
18 F 11.1 IT Primary None 11.1 II NR NED 8.4+
19 F 1.4 IT Primary None 1.5 II NR NED 8.4+
20 M 5.8 IT Primary None 5.8 II 2.5 DOD 3.4
21 M 12.8 IT Recurrent RT 14.5 II 0.8 DOD 3.5
22 M 0.8 IT Primary None 0.8 II 1.0 DOD 6.8
23 M 0.8 IT Recurrent C/RT 5.8 II 0.9 DOD 6.8
24 M 2.5 IT Recurrent C/RT 11.4 II 1.0 DOD 11.0
25 F 11.1 ST Primary None 11.1 III NR NED 6.4+
26 F 5.2 IT Primary None 5.2 III NR NED 4.9+
Abbreviations: IT, Infratentorial; ST, Supratentorial; C, Chemotherapy treatment; RT, Radiotherapy treatment; NR, No Relapse to date; AWD, Alive With Disease; NED,
No Evidence of Disease; DOD, Dead as a result Of the Disease;
*Based on standard WHO (World Health Organization) classification for ependymomas.
Note: The letters represent different samples from the same patient.
doi:10.1371/journal.pone.0025114.t001
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PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e25114Figure 1. Heat Map representations for miRNA expression in ependymomas and normal controls. (A) Unsupervised Hierarchical
Clustering of all normal brain control samples against the ependymomas used in this study. The clustering and tree are based on Pearson’s
correlation and were generated by the MeV 4.1 software according to Delta Ct values. The miRNAs that are not represented in this Figure were not
detected in any of the groups. (B) Higher magnification of the Unsupervised Hierarchical Clustering from panel A with the supporting tree showing
the separation between normal samples and ependymomas from different locations. Black, Normal controls; Yellow, Infratentorial samples; Orange,
Supratentorial samples. NB-I, Normal ependymal cells from infratentorial location; NB-S, Normal ependymal cells from Supratentorial location. (C)
miRNAs as Biomarkers in Ependymoma
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e25114Results
Characteristics of the patients and samples
Two frozen tumors and thirty-four FFPE specimens from
twenty-six patients were collected and analyzed. The clinicopath-
ologic characterstics of the samples used in this study are presented
in Table 1. Of the thirty-four specimens, eight samples represented
recurrent tumors from five patients. Twenty-six samples were from
the infratentorial location (IT) and eight samples were supraten-
torial (ST). Fourteen samples were primary tumors and twenty
represented recurrent tumors. The median age of our patient
cohort was 7.1 years (range 0.2 to 19.2 years). At the time of data
censoring, 9 patients were still alive and the remainder had
succumbed to the disease.
We sought to investigate the correlations of the clinicopatho-
logic variables of the patients used in our study. First, we evaluated
the differences in patient age at diagnosis (,3o r.3 year of age),
location (infratentorial versus supratentorial), prior treatment,
extent of resection, WHO grade, patient outcome (succumbed to
the disease, or alive with or without the disease) and tumor type
(primary versus recurrent) by Kaplan-Meier Curves. We have
found statistically significant differences in overall survival for
resection (p=0.0004), tumor type (p=0.01) and tumor location
(p=0.01) (Figure S2). On the other hand, we were not able to
identify any variable exhibiting significant correlation with time to
relapse. However, a trend in variables such as resection and prior
treatment (p=0.07) was observed (Figure S3). For all the other
variables both overall survival and time to relapse were not
statistically significant (data not shown).
microRNA expression profiling of ependymoma samples
In order to evaluate the correlation between frozen and paraffin
tissue from the same patient, we profiled the expression levels of
365 miRNAs in paired samples of two patients. The first pair of
specimens had been archived for 5 years and showed a high
correlation between FFPE and frozen tumor (r=0.99, p,0.05);
the second pair (archived for 10 years) also exhibited a strong
correlation (r=0.94, p,0.05, data not shown).
We then proceeded to evaluate miRNA expression in paraffin
samples from thirty-four ependymomas and compared them to
eight samples derived from normal brain tissue enriched for
ependymal cells (6 infratentorial and 2 supratentorial). Unsuper-
vised hierarchical clustering of miRNA expression levels revealed
that normal brain and ependymoma samples cluster independent-
ly (Figures 1A and 1B). On the other hand, many of the
supratentorial ependymomas cluster together, separated from the
infratentorial tumors (Figure 1B). However, two of the supraten-
torial tumors were disparate from the main supratentorial branch
(Figure 1B).
Twenty-eight miRNAs were identified as differentially ex-
pressed in ependymomas compared to normal controls
(Figure 1C, Table 2, p#0.01, FDR,0.05). We have verified that
miR-34a and miR-135a are over-expressed in our samples when
compared to normal controls. MiR-485-5p was identified in these
analyses as down-regulated in ependymomas when compared to
normal controls (Table 2 and Figure 1C). Using only differentially
expressed miRNAs, we generated a supervised hierarchical
clustering, which confirms that normal samples and tumors cluster
independently (Figure S1A). Individual assays were then per-
formed to confirm the over-expression (e.g. miR-135a and miR-
17-5p), and the down-regulation (e.g. miR-383 and miR-485-5p)
of a few selected miRNAs (Figure S1B).
Bioinformatic target predictions of differentially
expressed microRNAs
We have utilized both GoMir and GeneGo for target
identification of specific miRNAs that were significantly differen-
tially expressed in the comparisons shown in Table 2. Based on
gene expression data we have also evaluated the miRNA targets
that were predicted from the GeneGo networks (Table S2). Using
this strategy, we have identified putative targets for miRNAs that
were found to be down-regulated and over-expressed in
ependymomas. Accordingly, it is noteworthy that - as an example
- components of the TGFbeta pathway were identified as over-
expressed in ependymomas, and they are putative targets for miR-
485-5p (down-regulated in our analysis) (Table 2, Figure 1C and
Figure S1B).
microRNAs as potential biological markers in
ependymomas
We performed comparisons between the clinicopathological
variables and miRNAs and we identified miR-7, miR-31, miR-
107, miR-124a, miR-183, miR-339, miR-376a and miR-551a as
supratentorial-specific (Table 2). We have also identified miR-34a
as specifically over-expressed in supratentorial tumors (Table 2).
This observation was confirmed using individual assays for miR-
34a (data not shown).
Cox regressive analysis was used to select important clinical
variables in terms of association with Time to Relapse and
Overall Survival. miRNAs were selected by adding each miRNA
to the Cox model, one by one. First, using univariate regression
analyses we generated a list of statistically significant miRNAs,
which were associated with Overall Survival and Time to Relapse
(Table 3). Next, we determined the association of these select
miRNAs with clinical variables using a multivariate Cox
regression analysis. Importantly, miR-203 was identified as an
independent factor for Time to Relapse after adjustment for all
the known variables (Table 4). These data suggest that miR-203
could be used as a biomarker for management of disease
progression in ependymomas as a predictor for the likelihood of
recurrence (Table 4). We have also identified three miRNAs
(let7d, miR-596 and miR-367) as independent predictors for
Overall Survival (Table 4).
We found that miRNAs whose expression is associated with
time to relapse exhibited a strong correlation amongst themselves,
thus suggesting that they might be in the same network or pathway
(Figure 2A). Five of these (miR- 376a, miR-381, miR-411, miR-
432 and miR-487) map to human chromosome 14q32.31.
Interestingly, miR-203 also maps to human chromosome 14q32,
but to another location (14q32.33).
Finally, we used a survival tree method to determine the
thresholds of cut-off points for selected miRNAs based upon their
expression levels. We then generated Kaplan-Meier curves for our
cohort based upon the expression of the selected miRNAs mapped
to human chromosome 14q32. As shown in Figure 2B, all of these
miRNAs exhibited statistically significant associations to time to
relapse; except miR-203 that showed a trend towards significance.
Histogram graphical representation of the statistically differentially expressed miRNAs when comparing all normal samples against the ependymoma
samples used in this study. The values in the Y axis are of fold changes based on the StatMiner software. Twenty-eight miRNAs are differentially
expressed - twenty-three miRNAs are over-expressed and five miRNAs are downregulated (p#0.01; FDR,0.05).
doi:10.1371/journal.pone.0025114.g001
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higher expression was associated with a lower relapse free
probability. For miR-203, we observed that lower expression
correlated to a trend to develop recurrences (Figure 2B). In
conclusion, these data demonstrated that a cluster of miRNAs on
human chromosome 14q32 might be utilized as biomarkers for
this disease.
Discussion
Ependymoma is the most common pediatric brain tumor with a
heterogeneous clinical behavior. Attempts to predict outcomes
based on the molecular biology of this tumor have been largely
unsuccessful. Our group has already shown clinically relevant
epigenomic differences in ependymomas, especially in repetitive
regions of the genome [14]. In the present study, we have
generated miRNA expression profiles from ependymomas and
compared them with those of normal ependymal cells. The normal
cells used in this study were derived from normal brain tissue with
enrichment for ependymal cells, which originate from radial glial
cells, recently suggested as the cell of origin for ependymomas
[15]. We have shown that normal controls cluster separately from
ependymomas with regard to miRNA expression patterns.
Further, miRNA expression profiles were able to differentiate
subgroups of tumors from different locations in the brain as shown
for protein-coding genes [15], thus reinforcing the idea that
ependymomas from different parts of the CNS are distinct entities.
For example, Johnson et al. have demonstrated that miRNA
expression patterns can segregate tumors by location and
subgroup [16]. However, our study differs by the methods that
Table 2. miRNAs differentially expressed in ependymomas
(p#0.01, FDR,0.05).
miRNA E. vs C. I. vs IC. S. vs SC. I. vs S.
miR-7 -- - 246.0
miR-10a 38.1 - - -
miR-15a - 53.2 - -
miR-17-5p
1 62.4 109.6 - -
miR-19a 28.4 33.1 - -
miR-19b 20.9 25.6 - -
miR-193a - 58.0 - -
miR-20a 13.9 18.5 - -
miR-21 28.2 31.8 - -
miR-23a - 14.5 - -
miR-30b - 12.9 - -
miR-31 - 42.1 - 73.8
miR-32 28.2 57.2 - -
miR-34a
1 99.0 80.2 198.8 -
miR-106b 20.0 17.9 - -
miR-107 -- - 218.6
miR-124a -- - 261.1
miR-128b -- 247.6 -
miR-130a 34.8 43.9 - -
miR-130b - 14.3 - -
miR-135a
1 54.1 70.5 - -
miR-139 214.5 - - -
miR-142-3p 23.8 23.5 - -
miR-155 - 14.1 - -
miR-183 -- - 229.0
miR-193a 42.7 58.0 - -
miR-210 28.8 32.1 - -
miR-301 28.5 35.5 - -
miR-323 218.9 223.1 - -
miR-339 -- - 211.5
miR-376a -- - 215.8
miR-383
1 2120.7 2156.2 - -
miR-433 228.5 255.3 - -
miR-449b 40.3 54.1 - -
miR-485-5p
1 284.2 2197.8 - -
miR-502 48.8 62.9 - -
miR-518b 64.8 44.0 218.3 -
miR-551a - - 194.4 225.1
miR-551b 20.6 27.2 - -
miR-565 18.6 17.6 - -
miR-591 55.4 32.3 305.1 -
miR-594 79.6 79.2 83.7 -
miR-601 16.5 15.2 - -
Abbreviations: E, Ependymomas; C, All Normal Controls; I, Infratentorial
Tumors; IC, Infratentorial Normal Controls; S, Supratentorial Tumors; SC,
Supratentorial Normal Controls.
1miRs that were confirmed by individual assays.
Note: The cut off used in these analyses was 10 fold up and/or down with a
p#0.01 according to individual confirmation assays.
doi:10.1371/journal.pone.0025114.t002
Table 3. Selected miRNAs after adjusting the clinical variables
using Cox regression analyses for both Overall Survival and
Time-to-Relapse.
miRNA
Hazard Ratio
(95% CI)
Wald-Chisquare
statistics p-value
Overall Survival
let-7d 1.83(1.11, 3.02) 5.5473 0.0185
miR-596 1.32(1.05, 1.68) 5.3863 0.0203
miR-615 0.74(0.57, 0.96) 4.9653 0.0259
miR-107 1.33(1.03, 1.72) 4.6580 0.0309
miR-302d 0.69(0.48, 0.99) 4.1219 0.0423
miR-193b 0.71(0.50, 1.00) 3.9481 0.0469
miR-497 1.39(1.00, 1.93) 3.9034 0.0482
miR-367 0.75(0.56, 1.00) 3.8851 0.0487
Time-To-Relapse
miR-203 1.35(1.12, 1.63) 9.9520 0.0016
miR-20b 0.65(0.47, 0.92) 5.9878 0.0144
miR-213 0.75(0.59, 0.95) 5.5082 0.0189
miR-432 0.72(0.54, 0.95) 5.3630 0.0206
miR-184 1.20(1.03, 1.41) 5.2786 0.0216
miR-411 0.86(0.75, 0.98) 5.1908 0.0227
miR-376a 0.85(0.73, 0.98) 4.8401 0.0278
miR-381 0.84(0.72, 0.99) 4.6151 0.0317
miR-487b 0.83(0.69, 1.00) 3.8952 0.0484
miR-383 0.87(0.76, 1.00) 3.8949 0.0484
doi:10.1371/journal.pone.0025114.t003
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used Real-Time PCR and paraffin-embedded samples, whereas
Johnson et al. utilized miRNA microarray hybridization and frozen
tumor specimens. Notwithstanding the experimental differences,
our findings corroborate theirs in that both groups obtained
evidence to support the hypothesis that miRNA profiles are able to
subgroup tumors from different locations in the brain.
Studies over the last few years have contributed to our
understanding of the genetic abnormalities in ependymomas.
Altogether, these investigations have shed some light on the
molecular mechanisms underlying the development of ependymo-
mas, while proposing molecular markers of potential value for
tumor stratification that might be predictive of clinical behavior.
Comparative Genomic hydbirdization (CGH) analysis, for exam-
ple, have revealed genetic aberrations in ependymomas, such as
gains in chromossome 1q that are associated with a poor prognosis
[17]. On the other hand, loss of the 6q25.3 region has been
associated with improved prognosis [18]. Gene expression analysis
have identified molecular signatures in ependymomas that
comprise members of both the Notch and Hedgehog signaling
pathways [19]. Some studies have also shown that over-expression
of the human telomerase (hTERT) is a strong prognostic factor for
ependymomas [20]. In addition, ependymomas have shown
frequent gain and amplification of the EGFR gene located at
7p11.2 [13], as an independent prognostic factor for poor survival
[21]. Several agents targeting EGFR such as erlotinib and gefitinib
are currently in clinical trials and the anti-EGFR monoclonal
antibody C225 is also being investigated. However, the role of
these agents in the treatment of ependymomas remains elusive,
hence the urgency to identify better drug targets and molecular
biomarkers for this type of brain tumor.
Several lines of evidence have already shown that miRNAs are
implicated in the initiation and progression of malignancies.
Tumors that have specific miRNAs up- and/or downregulated
often exhibit more aggressive phenotypes. Hence, these miRNAs
can be exploited as prognostic markers [22]. This is expected
considering that a single miRNA can affect an entire network of
proteins and/or signaling pathway. In addition, not only may two
or more miRNAs act on the same network, they may also co-
operatively target a common transcript. These findings suggest
that albeit small in size, miRNAs are quite large in their impact to
cancer biology.
Initially, we compared the miRNA expression profiles of frozen
and paraffin tissue derived from the same patients, and we were
able to show a high correlation as previously reported by others
[23]. In our study, we were able to identify a miRNA signature
that can separate with a 100% certainty normal ependymal cells
from ependymomas. Specific miRNAs were confirmed as over-
expressed and down-regulated in ependymomas, such as miR-
135a, miR-34a, miR-17-5p, miR-383 and miR-485-5p (Figure
S1B). We were also able to identify computationally, and by gene
expression analysis, some putative targets for these miRNAs (Table
S1). Interestingly, we have identified 3 genes from the TGF beta
family as putative targets of miR-485-5p. It is noteworthy that the
TGF beta family of genes has been previously identified as
important in ependymomas and to other brain tumors [24,25].
A previous study showed that miR-10b was over-expressed in
malignant gliomas and in four ependymomas [26]. However, in
our study, miR-10b was not differentially expressed, which might
be due to sample size differences. On the other hand, we did find
miR-10a to be over-expressed in ependymomas in comparison to
normal controls (Table 2). This is noteworthy since these miRNAs
are part of the same miRNA family. Differential expression of
other miRNAs was associated to ependymomas [27]. This group
used a small sample size and miRNA expression profiling was
evaluated by microarray hybridization [27]. miR-21 was also
identified as being over-expressed in ependymomas [27]. Other
groups have already shown increased expression of miR-21 in
brain tumors [28,29] and we have demonstrated that this miR is
over-expressed in our samples.
We also report differential miRNA expression and its
association with clinicopathologic features in our patient cohort.
We have found concerted differential expression of miRNAs that
are organized in clusters in the genome. Accordingly, miRNAs in
the miR-17-92 genomic cluster, such as miR-17-5p, miR-19a,
miR-19b and miR-20a, were up-regulated in ependymomas
(Table 2). We have also observed site-specific expression for
miR-7, miR-31, miR-107, miR-124, miR-183, miR-339, miR-
376a and miR-551a, when comparing supratentorial to infraten-
torial tumors (Table 2). Using individual assays, we were able to
confirm that miR-34a is highly over-expressed in supratentorial
tumors relative to normal supratentorial controls. It is known that
supratentorial ependymomas tend to have a better prognosis. This
was indeed the case in our patient cohort: 2 out of 6 (33%) patients
Table 4. Multivariate Cox Regression Analyses for Time to Relapse and Overall Survival.
Variable Hazard Ratio 95% Confidence Interval of Hazard ratio p-value
Time-To-Relapse
Resection
(complete vs. incomplete)
0.17 0.06, 0.48 0.0008
Prior treatment
(none vs treated)
0.34 0.14,0.83 0.0175
WHO (II vs III) 0.21 0.076,0.57 0.0024
miR-203 (down vs up) 1.35 1.21,1.63 0.0016
Overall Survival
Resection
(complete vs. incomplete)
0.047 0.006, 0.28 0.0007
Let-7d (down6up) 2.78 1.31, 5.89 0.0076
miR-596 (down6up) 1.34 1.01, 1.78 0.0430
miR-367 (up vs down) 0.43 0.25, 0.76 0.0031
doi:10.1371/journal.pone.0025114.t004
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contrast to 15 out of 20 (75%) with an infratentorial tumor (Figure
S2A). Future studies will determine whether this observed altered
miRNA expression has significance to the differential clinical
behavior of supratentorial and infratentorial ependymomas.
We have applied Cox Regression analyses to identify miRNAs
with differential expression associated to both overall survival and
time to relapse (Table 3). Importantly, we have also demonstrated
significant concerted dysregulation of expression among the
miRNAs identified in the Cox Regression analyses (Figure 2A).
Based on these results, we hypothesized that some of these
miRNAs might be in the same genomic location, or under the
same regulatory control. Interestingly, 6 miRNAs identified in our
analyses are located in the same human chromosome, and five of
them are in the same genomic cluster. This cluster is mapped to
human chromosome 14q32.31, which is well known for the
presence of imprinted genes. We have further shown that miRNAs
from this imprinted cluster are associated with time to relapse in
our ependymoma cohort by Kaplan-Meier curves (Figure 2B).
This cluster of miRNAs is mapped to a genomic region that is
regulated by DNA methylation in both humans and mice [30],
and miRNAs from this genomic cluster have already been
associated to human malignancies [31]. This indicates that human
chromosome 14q32.31 may be implicated in the tumorigenesis of
ependymomas. Our findings highlight, for the first time, a strong
association of this imprinted cluster of miRNAs on 14q32.31 to the
development of ependymomas. These findings may direct future
investigations aimed at the development of new drugs and
therapies for ependymomas. However, more research is needed
to better understand the function of these miRNAs and the
expression of other genes mapped to the same genomic region.
Next, we performed multivariate analyses to determine if any of
these miRNAs could be of value as a biomarker for ependymomas.
Using this approach, we have shown that miRNA-203 down-
regulation is strongly associated with Time to Relapse (Table 4
and Figure 2A). We found it to be an independent prognostic
factor for recurrences with a hazard ratio that is almost ten times
higher than that of other known clinical features such as extent of
resection (Table 4). MiR-203 is also mapped to human
chromosome 14, however it is located at a distance of
approximately 3 megabases from the aforementioned imprinted
cluster of miRNAs identified in our univariate analyses. Impor-
tantly, previous studies have shown the association of miR-203 to
human cancers. For example, epigenetic silencing of miR-203 has
been implicated in the regulation of the BCR-ABL gene in
leukemia [32]. This miRNA has also been associated to skin
differentiation by repressing cell ‘‘stemness’’ [33]. Moreover, it was
recently shown that miR-203 expression in keratinocytes is
dependent on the regulation of the levels of the tumor suppressor
gene p53 [34]. MiR-203 expression was also associated to a worse
survival of patients with pancreatic tumors [35]. Finally, aberrant
expression of miR-203 was correlated to different clinicopatho-
logic variables in gastric and colorectal cancers [36]. Multivariate
analyses for Overall Survival also revealed that a member of the
let-7 miRNA family, let-7d, is a prognostic marker in ependymo-
mas (Table 4). The let-7 family has been extensively associated
with embryogenesis, pluripotency and cancers [37] Additionally,
miR-596 and miR-367 were also associated to Overall Survival
(Table 4). A few reports have implicated both miRNAs with
tumorigenesis and embryogenesis [38,39].
Notwithstanding the relatively small size of our patient cohort,
we were able to identify miRNAs of clinical importance. Our
results indicate, for the first time, that miRNAs might prove
invaluable as a biomarker for recurrence in ependymomas.
Additionally, we are further evaluating the molecular mechanisms
underlying the observed differential expression of miRNAs with
clinical significance. In conclusion, we were able to identify a
ependymoma-specific miRNA signature, a tumor site-specific
miRNA profile that enables stratification of intracranial ependy-
momas according to region of occurrence (infratentorial or
supratentorial), and altered miRNA expression associated to
certain clinical behavior. We have identified a miRNA cluster in
an imprinted region of human chromosome 14q32 that is
associated to a worse prognosis in ependymomas. Specifically,
miR-203 was identified as an independent prognostic marker for
time to relapse compared to the clinical variables that are presently
utilized in the clinics. Moreover, let-7d, miR-596 and miR-367
were strongly associated to Overall Survival. We are currently
working to confirm some of the predicted targets for these
miRNAs. We believe that these findings will pave new ways for the
development of therapies and for a better management of this type
of pediatric brain tumor.
Supporting Information
Figure S1 Supervised hierarchical clustering and Individual
confirmation for 4 differentially expressed miRNAs in ependymo-
mas. (A) Supervised Hierarchical Clustering with twenty-eight
miRNAs identified as differentially expressed in ependymomas
when compared to normal controls (p#0.01,FDR,0.05). The
clustering and tree are based on Pearson’s correlation and were
generated by the MeV 4.1 software according to Delta Ct values.
(B) Histograms for individual assays were generated by the
StatMiner software and represent fold change differences using
individual TaqMan Real-Time PCR assays for normal controls
and ependymoma samples (p#0.05). Over-expressed miRs (miR-
135a and miR-17-5p) and down-regulated miRNAs (miR-383 and
miR-485-5p) are represented.
(AI)
Figure S2 Kaplan-Meier curves for Overall Survival (OS) based
on the Log Rank Test using all the samples in this study for
clinicopathologic variables. (A) Tumor Location, (B) Resection
and (C) Tumor Specimen.
(AI)
Figure S3 Kaplan-Meier curves for Time to Relapse based on
the Log Rank Test using all the samples in this study for
clinicopathologic variables. (A) Resection, (B) Prior treatment.
(AI)
Table S1 List of microRNAs present in the TLDA array v1.0
that were used in this study.
(PDF)
Figure 2. miRNAs and correlations to clinicopathological features. (A) Correlation matrix among miRNAs that were identified by Cox
regression analyses for Time to Relapse. The lower triangle of the matrix shows the scatter plots of pair-wised relationship between miRNAs. The
diagonal panel shows histograms of expression. The upper triangle represents Spearman correlation coefficients for each pair of miRNA (B) Kaplan-
Meier curves of a cluster of miRNAs on human chromosome 14q32 and associations to Time to Relapse. The thresholds of cut-off points were
determined using a survival tree analysis approach. Delta CT values were used for miRNA expression in this analysis. The Y axis represents relapse free
probability and the X axis represents time of follow-up in years.
doi:10.1371/journal.pone.0025114.g002
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